新兴传染病疫苗：中东呼吸综合征冠状病毒和寨卡病毒带来的启示。
Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.
机构信息
a GeneOne Life Science, Inc. Seoul , Korea.
出版信息
Hum Vaccin Immunother. 2017 Dec 2;13(12):2918-2930. doi: 10.1080/21645515.2017.1358325. Epub 2017 Aug 28.
Abstract
The past decade and a half has been characterized by numerous emerging infectious diseases. With each new threat, there has been a call for rapid vaccine development. Pathogens such as the Middle East Respiratory Syndrome coronavirus (MERS-CoV) and the Zika virus represent either new viral entities or viruses emergent in new geographic locales and characterized by novel complications. Both serve as paradigms for the global spread that can accompany new pathogens. In this paper, we review the epidemiology and pathogenesis of MERS-CoV and Zika virus with respect to vaccine development. The challenges in vaccine development and the approach to clinical trial design to test vaccine candidates for disease entities with a changing epidemiology are discussed.
摘要
过去十五年的时间里出现了许多新发传染病。每出现一种新的威胁，就会有人呼吁快速开发疫苗。中东呼吸综合征冠状病毒（MERS-CoV）和寨卡病毒等病原体要么是新的病毒实体，要么是在新的地理区域出现的新型病毒，并具有新的并发症。两者都可作为伴随新病原体出现的全球传播的范例。在本文中，我们将回顾 MERS-CoV 和寨卡病毒的流行病学和发病机制，以及它们在疫苗开发方面的情况。讨论了疫苗开发所面临的挑战，以及针对具有不断变化的流行病学的疾病实体测试疫苗候选物的临床试验设计方法。
相似文献
1
Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.
Hum Vaccin Immunother. 2017 Dec 2;13(12):2918-2930. doi: 10.1080/21645515.2017.1358325. Epub 2017 Aug 28.
2
Vaccine development for emerging virulent infectious diseases.
Vaccine. 2017 Oct 4;35(41):5437-5443. doi: 10.1016/j.vaccine.2017.02.015. Epub 2017 Feb 16.
3
Receptor-binding domain-based subunit vaccines against MERS-CoV.
Virus Res. 2015 Apr 16;202:151-9. doi: 10.1016/j.virusres.2014.11.013. Epub 2014 Nov 20.
4
Vaccines for the prevention against the threat of MERS-CoV.
Expert Rev Vaccines. 2016 Sep;15(9):1123-34. doi: 10.1586/14760584.2016.1167603. Epub 2016 Apr 6.
5
A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
J Virol. 2015 Nov;89(22):11654-67. doi: 10.1128/JVI.01815-15. Epub 2015 Sep 9.
6
Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus.
Microbes Infect. 2018 Dec;20(11-12):676-684. doi: 10.1016/j.micinf.2018.03.001. Epub 2018 Mar 17.
7
Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.
Hum Vaccin Immunother. 2018 Feb 1;14(2):304-313. doi: 10.1080/21645515.2017.1389362. Epub 2017 Nov 29.
8
Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches.
Curr Opin Virol. 2017 Apr;23:49-58. doi: 10.1016/j.coviro.2017.03.007. Epub 2017 Apr 13.
9
Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development.
Hum Vaccin Immunother. 2019;15(10):2258-2263. doi: 10.1080/21645515.2019.1634992. Epub 2019 Jul 16.
10
Zika Virus Vaccine Development: Progress in the Face of New Challenges.
Annu Rev Med. 2019 Jan 27;70:121-135. doi: 10.1146/annurev-med-040717-051127. Epub 2018 Nov 2.
引用本文的文献
1
A novel approach to designing viral precision vaccines applied to SARS-CoV-2.
Front Cell Infect Microbiol. 2024 Apr 2;14:1346349. doi: 10.3389/fcimb.2024.1346349. eCollection 2024.
2
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
mSystems. 2023 Apr 27;8(2):e0092722. doi: 10.1128/msystems.00927-22. Epub 2023 Mar 2.
3
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
ArXiv. 2023 Jan 23:arXiv:2208.08907v2.
4
Keeping up with the COVID's-Could siRNA-based antivirals be a part of the answer?
Exploration (Beijing). 2022 Jul 14;2(6):20220012. doi: 10.1002/EXP.20220012.
5
Planetary health & COVID-19: A multi-perspective investigation.
One Health. 2022 Dec;15:100416. doi: 10.1016/j.onehlt.2022.100416. Epub 2022 Jul 22.
6
Co-administration of a plasmid encoding CD40 or CD63 enhances the immune responses to a DNA vaccine against bovine viral diarrhea virus in mice.
J Vet Med Sci. 2022 Sep 1;84(9):1175-1184. doi: 10.1292/jvms.22-0085. Epub 2022 Jul 7.
7
Recent Update of COVID-19 Vaccines.
Adv Pharm Bull. 2022 Mar;12(2):219-236. doi: 10.34172/apb.2022.045. Epub 2021 Oct 4.
8
COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review.
3 Biotech. 2022 Jan;12(1):15. doi: 10.1007/s13205-021-03076-0. Epub 2021 Dec 12.
9
SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
GastroHep. 2021 Jul;3(4):212-228. doi: 10.1002/ygh2.473. Epub 2021 Jul 23.
10
Vaccine against SARS-CoV-2: Challenges and considerations.
Can Commun Dis Rep. 2021 Mar 31;47(3):128-131. doi: 10.14745/ccdr.v47i03a01.
本文引用的文献
1
protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.
NPJ Vaccines. 2016 Nov 10;1:16021. doi: 10.1038/npjvaccines.2016.21. eCollection 2016.
2
Maternal Zika Virus Disease Severity, Virus Load, Prior Dengue Antibodies, and Their Relationship to Birth Outcomes.
Clin Infect Dis. 2017 Sep 15;65(6):877-883. doi: 10.1093/cid/cix472.
3
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
Cell. 2017 May 4;169(4):597-609.e11. doi: 10.1016/j.cell.2017.04.024.
4
Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys.
Cell. 2017 May 4;169(4):610-620.e14. doi: 10.1016/j.cell.2017.04.008. Epub 2017 Apr 27.
5
Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection.
Emerg Infect Dis. 2017 May;23(5):773-781. doi: 10.3201/eid2305.161630.
6
Zika Virus Infection and Associated Neurologic Disorders in Brazil.
N Engl J Med. 2017 Apr 20;376(16):1591-1593. doi: 10.1056/NEJMc1608612. Epub 2017 Mar 29.
7
A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models.
Nat Med. 2017 Jun;23(6):763-767. doi: 10.1038/nm.4322. Epub 2017 Apr 10.
8
Viral and serological kinetics in Zika virus-infected patients in South Korea.
Virol J. 2017 Apr 7;14(1):70. doi: 10.1186/s12985-017-0740-6.
9
Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.
Science. 2017 Apr 14;356(6334):175-180. doi: 10.1126/science.aal4365. Epub 2017 Mar 30.
10
Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
Sci Rep. 2017 Mar 23;7:44875. doi: 10.1038/srep44875.
Zotero 插件